Post Kala-Azar Dermal Leishmaniasis following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) for Primary Visceral Leishmaniasis in Bihar, India

PLoS Neglected Tropical Diseases

Volumn 8, Issue 1, 2014, Pages 49-

  Burza, Sakib ^a   Sinha, Prabhat Kumar ^b   Mahajan, Raman ^a   Sanz, Marta González ^a   Lima, María Angeles ^a   Mitra, Gaurab ^a   Verma, Neena ^b   Das, Pradeep ^b  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b RAJENDRA MEMORIAL RESEARCH INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; AMPHOTERICIN B; ANTIPROTOZOAL AGENT;

ADOLESCENT; ADULT; ARTICLE; CHILD; COHORT ANALYSIS; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEALTH PROGRAM; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; RISK FACTOR; SKIN LEISHMANIASIS; TREATMENT OUTCOME; TREATMENT RESPONSE; VISCERAL LEISHMANIASIS; INFANT; ISOLATION AND PURIFICATION; LEISHMANIA DONOVANI; MIDDLE AGED; PRESCHOOL CHILD; RECURRENT DISEASE; TREATMENT FAILURE; YOUNG ADULT;

ADOLESCENT; ADULT; AMPHOTERICIN B; ANTIPROTOZOAL AGENTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; INDIA; INFANT; LEISHMANIA DONOVANI; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT FAILURE; YOUNG ADULT;

EID: 84893808880     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002611     Document Type: Article

References (21)

1. Ramesh V, Mukherjee A, (1995) Post-kala-azar dermal leishmaniasis. Int J Dermatol 34: 85-91 doi:10.1111/j.1365-3156.2007.01854.x.
2. Zijlstra EE, El-Hassan AM, (2001) Leishmaniasis in Sudan: post kala-azar dermal leishmaniasis. Trans R Soc Trop Med Hyg 95: S59-S76.
3. Ramesh V, Singh R, Salotra P, (2007) Post-kala-azar dermal leishmaniasis - an appraisal. Trop Med Int Health 12: 848-851.
4. Singh S, Sharma U, Mishra J, (2011) Post-kala-azar dermal leishmaniasis: Recent developments. Int J Dermatol 50: 1099-1108 doi:10.1111/j.1365-4632.2011.04925.x.
5. Croft SL, (2008) PKDL - A drug related phenomenon? Indian J Med Res 128: 10-11.
6. Addy M, Nandy A, (1992) Ten years of kala-azar in West Bengal. Part I. Did post-kala-azar dermal leishmaniasis initiate the outbreak in 24-Parganas? Bull World Health Organ 70: 341-346.
7. World Health Organization (2012) Post-kala-azar dermal leishmaniasis: a manual for case management and control: Report of a WHO consultative meeting, Kolkata, India. ISBN 978 92 4 150521 5.
8. Balasegaram M, Ritmeijer K, Lima MA, Burza S, Ortiz Genovese G, et al. (2012) Liposomal amphotericin B as a treatment for human leishmaniasis. Expert Opin Emerg Drugs 17: 493-510 10.1517/14728214.2012.748036; 10.1517/14728214.2012.748036.
9. Das VN, Ranjan A, Pandey K, Singg D, Verma N, et al. (2012) Clinical epidemiologic profile of a cohort of post-kala-azar dermal leishmaniasis patients in Bihar, India. Am J Trop Med Hyg 86: 959.
10. Zijlstra EE, Musa AM, Khalil EA, el-Hassan IM, el-Hassan AM, (2003) Post-kala-azar dermal leishmaniasis. Lancet Infect Dis 3: 87-98.
11. Rahman KM, Islam S, Rahman MW, Kenah E, Chowdhury MG, et al. (2010) Increasing incidence of post-kala-azar dermal leishmaniasis in a population based study in Bangladesh. Clin Infect Dis 50: 73-76 doi:10.1086/648727.
12. Sharma MC, Gupta AK, Verma N, Das VN, Saran R, et al. (2000) Demonstration of Leishmania parasites in skin lesions of Indian post kala-azar dermal leishmaniasis (PKDL) cases. J Commun Dis Mar;32 (1):: 67-8.
13. Mondal D, Nasrin KN, Huda MM, Kabir M, Hossain MS, et al. (2010) Enhanced Case Detection and Improved Diagnosis of PKDL in a Kala-azar-Endemic Area of Bangladesh. PLoS Negl Trop Dis 4: e832 doi:10.1371/journal.pntd.0000832.
14. Uranw S, Ostyn B, Rijal A, Devkota S, Khanal B, et al. (2011) Post-Kala-azar Dermal Leishmaniasis in Nepal: A Retrospective Cohort Study (2000-2010). PLoS Negl Trop Dis 5: e1433 doi:10.1371/journal.pntd.0001433.
15. Mukhopadhyay D, Das NK, De Sarkar S, Manna A, Ganguly DN, et al. (2012) Evaluation of serological markers to monitor the disease status of Indian post kala-azar dermal leishmaniasis. Trans R Soc Trop Med Hyg 106: 668-76 doi:10.1016/j.trstmh.2012.07.005.
16. National Vector Borne Disease Control Programme (NVBDCP). Kala-azar cases and deaths in the country since 2007. Dehli: Ministry of Health & Family Welfare. Available: http://www.nvbdcp.gov.in/ka-cd.html. Accessed 30 May 2013.
17. Thakur CP, Narain S, Kumar N, Hassan SM, Jha DK, et al. (1997) Amphotericin B is superior to sodium antimony gluconate in the treatment of Indian post-kala-azar dermal leishmaniasis. Ann Trop Med Parasitol 91: 611-616.
18. Mookerjee Basu J, Mookerjee A, Sen P, Bhaumik S, Banerjee S, et al. (2006) Sodium antimony gluconate induces generation of reactive oxygen species and nitric oxide via phosphoinositide 3-kinase and mitogen-activated protein kinase activation in Leishmania donovani-infected macrophages. Antimicrob Agents Chemother 50: 1788-1797.
19. Banerjee A, De M, Ali N, (2008) Complete cure of experimental visceral leishmaniasis with amphotericin B in stearylamine-bearing cationic liposomes involves down-regulation of IL-10 and favorable T cell responses. J Immunol 181: 1386-1398.
20. Simitsopoulou M, Roilides E, Dotis J, Dalakiouridou M, Dudkova F, et al. (2005) Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin B. Antimicrob Agents Chemother Apr;49 (4):: 1397-403.
21. World Health Organisation (2010) Control of the leishmaniases. Report of a meeting of the WHO expert committee on the control of leishmaniases. WHO Technical Report Series no. 949. Geneva: WHO. Available: http://whqlibdoc.who.int/trs/WHO_TRS_949_eng.pdf. Accessed 30 May 2013.